These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22908139)

  • 21. Preface. Emerging targets and therapeutics in the treatment of psychostimulant abuse.
    Dwoskin LP
    Adv Pharmacol; 2014; 69():xi-xiii. PubMed ID: 24484989
    [No Abstract]   [Full Text] [Related]  

  • 22. Methamphetamine abuse: an overview for health care professionals.
    Wolkoff DA
    Hawaii Med J; 1997 Feb; 56(2):34-6, 44. PubMed ID: 9063008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of gelatine capsules for application of methamphetamine: a new harm reduction approach.
    Mravčík V; Skařupová K; Orlíková B; Zábranský T; Karachaliou K; Schulte B
    Int J Drug Policy; 2011 Mar; 22(2):172-3. PubMed ID: 21242079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crystal methamphetamine and the dental patient.
    Venker D
    Iowa Dent J; 1999 Oct; 85(4):34. PubMed ID: 11935809
    [No Abstract]   [Full Text] [Related]  

  • 25. Mephedrone related fatalities: a review.
    Busardò FP; Kyriakou C; Napoletano S; Marinelli E; Zaami S
    Eur Rev Med Pharmacol Sci; 2015 Oct; 19(19):3777-90. PubMed ID: 26502870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On the necessity of translational cognitive-neurotoxicological research in methamphetamine abuse and addiction.
    Stock AK; Beste C
    Arch Toxicol; 2017 Jul; 91(7):2707-2709. PubMed ID: 28444486
    [No Abstract]   [Full Text] [Related]  

  • 27. Stimulant Use Disorders.
    Park TM; Haning WF
    Child Adolesc Psychiatr Clin N Am; 2016 Jul; 25(3):461-71. PubMed ID: 27338967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current data on methamphetamine].
    Cottencin O; Rolland B; Guardia D; Karila L
    Rev Prat; 2012 May; 62(5):679-81. PubMed ID: 22730802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final Order.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2011 Oct; 76(204):65371-5. PubMed ID: 22016903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myocardial infarction after intranasal methamphetamine.
    Farnsworth TL; Brugger CH; Malters P
    Am J Health Syst Pharm; 1997 Mar; 54(5):586-7. PubMed ID: 9066872
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of intranasal methamphetamine and d-amphetamine self-administration by humans.
    Kirkpatrick MG; Gunderson EW; Johanson CE; Levin FR; Foltin RW; Hart CL
    Addiction; 2012 Apr; 107(4):783-91. PubMed ID: 22050030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The bioavailability of intranasal and smoked methamphetamine.
    Harris DS; Boxenbaum H; Everhart ET; Sequeira G; Mendelson JE; Jones RT
    Clin Pharmacol Ther; 2003 Nov; 74(5):475-86. PubMed ID: 14586388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meth mouth severity in response to drug-use patterns and dental access in methamphetamine users.
    Brown RE; Morisky DE; Silverstein SJ
    J Calif Dent Assoc; 2013 Jun; 41(6):421-8. PubMed ID: 23875434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Commentary on Marshall et al. (2010): are long-term negative health consequences of methamphetamine use important to youth?
    Rawson RA; Gonzales R
    Addiction; 2010 Jun; 105(6):1003-4. PubMed ID: 20659060
    [No Abstract]   [Full Text] [Related]  

  • 35. Smokable ("ice", "crystal meth") and non smokable amphetamine-type stimulants: clinical pharmacological and epidemiological issues, with special reference to the UK.
    Schifano F; Corkery JM; Cuffolo G
    Ann Ist Super Sanita; 2007; 43(1):110-5. PubMed ID: 17536161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increases in noninjection methamphetamine use in men who have sex with men, men who do not have sex with men, and Latino men diagnosed with AIDS in Los Angeles County, 2000 through 2004.
    Wohl AR; Johnson DF; Frye DM
    J Acquir Immune Defic Syndr; 2007 Aug; 45(5):601-3. PubMed ID: 17704687
    [No Abstract]   [Full Text] [Related]  

  • 37. Patterns of Use, Acute Subjective Experiences, and Motivations for Using Synthetic Cathinones ("Bath Salts") in Recreational Users.
    Ashrafioun L; Bonadio FA; Baik KD; Bradbury SL; Carhart VL; Cross NA; Davis AK; Feuille M; Harper AR; Lackey JH; Lang B; Lauritsen KJ; Leith J; Osborn LA; Rosenberg H; Stock J; Zaturenskaya M
    J Psychoactive Drugs; 2016; 48(5):336-343. PubMed ID: 27681583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. UK places generic ban on mephedrone drug family.
    Morris K
    Lancet; 2010 Apr; 375(9723):1333-4. PubMed ID: 20405534
    [No Abstract]   [Full Text] [Related]  

  • 39. Synthetic psychoactive cathinones: hypothermia and reduced lethality compared to methamphetamine and methylenedioxymethamphetamine.
    Muskiewicz DE; Resendiz-Gutierrez F; Issa O; Hall FS
    Pharmacol Biochem Behav; 2020 Apr; 191():172871. PubMed ID: 32061662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "Bath salts"-induced psychosis and serotonin toxicity.
    Joksovic P; Mellos N; van Wattum PJ; Chiles C
    J Clin Psychiatry; 2012 Aug; 73(8):1125. PubMed ID: 22967774
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.